Allucent, a global specialty CRO serving small and mid-sized biopharma, announced new therapeutic strategy leaders across its Allucent Centers of Expertise (ACEs), including oncology, neuroscience, cardiometabolic diseases, and immunology & inflammation. Allucent also announced a head of advanced therapeutics spanning rare disease and cell and gene therapy (CGT) programs. These new roles aim to support emerging biopharma innovation across complex therapeutic areas and advanced modalities....